Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlisimod
- Development stage
- Phase 2
- Lead developer
- Silk Technologies
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Amlisimod is a water-based ophthalmic eye-drop formulation composed of a mixture of peptides rich in glycine, alanine, serine, tyrosine, and valine residues produced by hydrolysis of Bombyx mori (silk) fibroin. It is being developed by SilkTech Biopharmaceuticals for the treatment of dry eye disease (keratoconjunctivitis sicca). The drug acts as an anti-inflammatory agent through inhibition of I-kappa B kinase (IKK), thereby suppressing NF-kappa-B signaling pathways involved in ocular surface inflammation. Amlisimod has reached phase II clinical trials for dry eye disease[1][2][3][4].
- Brand names
- SDP-4 Ophthalmic SolutionSDP4 Ophthalmic SolutionSDP 4 Ophthalmic Solution
- Other names
- amlisimodsilk derived protein 4
02
Targets
CHUK (IKKα)
Beyond the preview
Go deeper on amlisimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlisimod.